Department of Breast and Thyroid Surgery, Beijing Haidian Hospital, Beijing, China.
Department of Pathology, Beijing Haidian Hospital, Beijing, China.
Am Surg. 2024 Dec;90(12):3209-3215. doi: 10.1177/00031348241265143. Epub 2024 Jul 24.
This study aimed to analyze the malignant probability of thyroid nodules diagnosed as indeterminate cytology, including atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS), and investigate the diagnostic value of combining BRAF V600E gene testing within this classification.
We conducted a retrospective analysis of 126 patients who underwent fine-needle aspiration (FNA) examination of thyroid nodules and subsequent surgical treatment at Beijing Haidian Hospital between October 2021 and November 2022. Among them, there were 22 male and 104 female patients, aged between 18 and 75 years old. Surgical pathology results were considered the gold standard for diagnosing the nature of thyroid nodules, evaluating the malignant incidence of cytological results categorized as AUS/FLUS. Fisher's exact test and diagnostic test evaluation methods were used to analyze the discriminatory diagnostic efficacy of preoperative FNA combined with BRAF V600E gene testing for papillary thyroid carcinoma (PTC). Statistical analysis was performed using SPSS 22.0 software
In PTC patients, the BRAF V600E gene mutation rate was 87.93% (102/116). Within the category of FNA results as AUS/FLUS, the proportion of PTC was 60.00% (15/25). The specificity, sensitivity, positive predictive value, and negative predictive value of the BRAF V600E gene mutation in diagnosing PTC within the AUS/FLUS category were 10/10, 6/15, 6/6, and 10/19, respectively. The BRAF V600E gene mutation significantly increased the detection rate of PTC in patients classified under this cytology ( = 0.028, <0.05).
Preoperative FNA combined with BRAF V600E gene mutation testing significantly enhances the malignant detection rate of thyroid nodules diagnosed cytologically as AUS/FLUS. This combined approach provides a potent tool to improve diagnostic accuracy in this indeterminate classification.
本研究旨在分析甲状腺结节细胞学诊断为不确定意义的不典型性或滤泡性病变不典型(AUS/FLUS)的恶性概率,并探讨在该分类中联合 BRAF V600E 基因检测的诊断价值。
我们对 2021 年 10 月至 2022 年 11 月在北京海淀医院接受甲状腺结节细针穿刺(FNA)检查和随后手术治疗的 126 例患者进行了回顾性分析。其中,男性 22 例,女性 104 例,年龄 18 至 75 岁。手术病理结果被认为是诊断甲状腺结节性质的金标准,用于评估细胞学结果为 AUS/FLUS 的恶性发生率。Fisher 确切检验和诊断试验评估方法用于分析术前 FNA 联合 BRAF V600E 基因检测对甲状腺乳头状癌(PTC)的鉴别诊断效果。统计分析使用 SPSS 22.0 软件进行。
在 PTC 患者中,BRAF V600E 基因突变率为 87.93%(102/116)。在 FNA 结果为 AUS/FLUS 的类别中,PTC 的比例为 60.00%(15/25)。BRAF V600E 基因突变在诊断 AUS/FLUS 类别中的 PTC 时的特异性、敏感性、阳性预测值和阴性预测值分别为 10/10、6/15、6/6 和 10/19。BRAF V600E 基因突变显著提高了细胞学分类为 AUS/FLUS 的患者中 PTC 的检出率(=0.028,<0.05)。
术前 FNA 联合 BRAF V600E 基因突变检测显著提高了细胞学诊断为 AUS/FLUS 的甲状腺结节的恶性检出率。这种联合方法为提高该不确定分类的诊断准确性提供了有力工具。